80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]劉合亮,林煜,鄭世雄,等.青娥丸調(diào)控PERK/eIF2α/ATF4/CHOP通路對(duì)成骨細(xì)胞凋亡的影響[J].福建醫(yī)藥雜志,2025,47(03):66-71.[doi:10.20148/j.fmj.2025.03.017]
　LIU Heliang,LIN Yu,ZHENG Shixiong,et al.Mechanism of Qing'E formula regulating PERK/eIF2α/ATF4/CHOP pathway and its impact on osteoblast apoptosis[J].FUJIAN MEDICAL JOURNAL,2025,47(03):66-71.[doi:10.20148/j.fmj.2025.03.017]
點(diǎn)擊復(fù)制

青娥丸調(diào)控PERK/eIF2α/ATF4/CHOP通路對(duì)成骨細(xì)胞凋亡的影響()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
47
期數(shù):
2025年03期
頁碼:
66-71
欄目:
基礎(chǔ)研究
出版日期:
2025-03-20

文章信息/Info

Title:
Mechanism of Qing'E formula regulating PERK/eIF2α/ATF4/CHOP pathway and its impact on osteoblast apoptosis
文章編號(hào):
1002-2600(2025)03-0066-06
作者:
劉合亮; 林煜; 鄭世雄; 肖莉莉
福建省福州市第二總醫(yī)院,福州 350007
Author(s):
LIU Heliang;  LIN Yu;  ZHENG Shixiong;  XIAO Lili
Department of Orthopedics, Fuzhou Second General Hospital, Fuzhou, Fujian 350007, China
關(guān)鍵詞:
絕經(jīng)后骨質(zhì)疏松癥;  青娥丸;  內(nèi)質(zhì)網(wǎng)應(yīng)激;  PERK/eIF2α/ATF4/CHOP信號(hào)通路
Keywords:
postmenopausal osteoporosis;  Qing'E formula;  endoplasmic reticulum stress;  PERK/eIF2α/ATF4/CHOPsignaling pathway
分類號(hào):
R816.8
DOI:
10.20148/j.fmj.2025.03.017
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的 基于PERK/eIF2α/ATF4/CHOP信號(hào)通路探討青娥丸含藥血清對(duì)氧化應(yīng)激誘導(dǎo)內(nèi)質(zhì)網(wǎng)應(yīng)激凋亡成骨細(xì)胞系的保護(hù)作用及其作用機(jī)制。方法 30只雄性SD大鼠隨機(jī)分為生理鹽水組和青娥丸組,每組15只,分別給予生理鹽水和青娥丸灌胃干預(yù),連續(xù)7 d,腹主動(dòng)脈取全血制備含藥血清; 培養(yǎng)UMR-106細(xì)胞株,CCK-8篩選青娥丸和GSK2606414最佳干預(yù)濃度,細(xì)胞分為空白組、模型組、青娥丸組和抑制劑組,進(jìn)一步采用10 μmol/L的H2O2干預(yù)細(xì)胞12 h制備內(nèi)質(zhì)網(wǎng)應(yīng)激模型,CCK-8檢測4組細(xì)胞的增殖活性,DCFH-DA檢測細(xì)胞活性氧(ROS)含量,Real-time PCR和Western blot檢測PERK、eIF2α、ATF4、CHOP mRNA和蛋白的相對(duì)表達(dá)量。結(jié)果 青娥丸含藥血清最佳干預(yù)濃度為10%,GSK2606414最佳干預(yù)濃度為4%,此最佳干預(yù)濃度用于后續(xù)實(shí)驗(yàn)。H2O2干預(yù)后模型組細(xì)胞增殖活性顯著降低,ROS含量顯著升高,PERK、eIF2α、ATF4、CHOP mRNA和蛋白的相對(duì)表達(dá)量顯著上調(diào); 青娥丸組增殖活性增強(qiáng),ROS含量顯著降低,PERK、eIF2α、ATF4、CHOP mRNA和蛋白的相對(duì)表達(dá)量下調(diào)。結(jié)論 青娥丸含藥血清可有效抑制成骨細(xì)胞系的內(nèi)質(zhì)網(wǎng)應(yīng)激凋亡,其作用機(jī)制可能與PERK/eIF2α/ATF4/CHOP信號(hào)通路相關(guān)。
Abstract:
Objective To examine the protective effects and its mechanism of Qing'E formula serum on osteoblast apoptosis caused by oxidative stress-induced endoplasmic reticulum stress, focusing on the PERK/eIF2α/ATF4/CHOP signaling pathway. Methods Thirty male SD rats were randomly assigned to receive either normal saline or Qing'E formula via gavage for seven days to prepare drug-containing serum from abdominal aorta blood. UMR-106 cells were cultured, CCK-8 was selected for the optimal intervention concentration of Qing'E formula and GSK2606414. Cells were categorized into blank, model, Qing'E formula, and positive drug groups. The endoplasmic reticulum stress model was created by treating cells with 10 μmol/L H2O2 for 12 hours. Cell proliferation was assessed using CCK-8, ROS levels were dectected with DCFH-DA, and the expression levels of PERK, eIF2α, ATF4, and CHOP mRNA and protein were detected through Real-time PCR and Western blot. Results The optimal concentrations for Qing'E formula serum and GSK2606414 were found to be 10% and 4%, respectively. This optimal intervention concentration was used for subsequent experiments. Post-H2O2 treatment, the model group showed reduced cell proliferation, increased ROS, and elevated PERK, eIF2α, ATF4, and CHOP expression. Conversely, the Qing'E formula group exhibited increased proliferation, reduced ROS, and decreased expression of the above related markers. Conclusion Qing'E formula serum effectively inhibits endoplasmic reticulum stress-induced apoptosis in osteoblasts, possibly through the PERK/eIF2α/ATF4/CHOP signaling pathway.

參考文獻(xiàn)/References:

[1] Silverstein W K,Cantor N,Cheung A M.Postmenopausal osteoporosis[J].N Engl J Med,2024,390(7):673-674.
[2] Zhao F,GuoChandran M.AACE/ACE clinical practice guide-lines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update:risk stratification and intervention thresholds[J].Endocr Pract,2021,27(4):378.
[3] Zhao F,Guo L,Wang X,et al.Correlation of oxidative stress-related biomarkers with postmenopausal osteoporosis:a systematic review and meta-analysis[J].Arch Osteoporos,2021,16(1):4.
[4] Tao H,Ge G,Liang X,et al.ROS signaling cascades:dual regulations for osteoclast and osteoblast[J].Acta Biochim Biophys Sin(Shanghai),2020,52(10):1055-1062.
[5] 李超,趙劍波,陳俊雅,等.金天格膠囊對(duì)H2O2誘導(dǎo)的小鼠成骨細(xì)胞MC3T3-E1氧化應(yīng)激損傷及炎癥因子的作用[J].中國骨質(zhì)疏松雜志,2022,28(10):1448-1452,1532.
[6] 徐昊.雌激素對(duì)小鼠成骨細(xì)胞MC3T3-E1氧化應(yīng)激損傷的保護(hù)作用及機(jī)制探究[J].中國實(shí)驗(yàn)動(dòng)物學(xué)報(bào),2020,28(6):824-830.
[7] 蔣華,韓巖峰,羅琳,等.白藜蘆醇對(duì)絕經(jīng)后骨質(zhì)疏松女性骨代謝和氧化代謝產(chǎn)物水平的影響[J].中國骨質(zhì)疏松雜志,2019,25(4):523-527.
[8] 陳帆,魏戌,崔鑫,等.青娥丸治療絕經(jīng)后骨質(zhì)疏松癥的系統(tǒng)評(píng)價(jià)及Meta分析[J].中國骨質(zhì)疏松雜志,2021,27(2):179-189.
[9] Xiong J L,Cai X Y,Zhang Z J,et al.Elucidating the estrogen-like effects and biocompatibility of the herbal components in the Qing'E formula[J].J Ethnopharmacol,2022,283:114735.
[10] 王曉燕,常時(shí)新,李冠武,等.經(jīng)方青娥丸對(duì)去勢大鼠骨質(zhì)疏松作用機(jī)制的實(shí)驗(yàn)研究[J].中國骨質(zhì)疏松雜志,2017,23(2):197-202.
[11] 翁澤斌,顏翠萍,張志杰,等.不同炮制品入藥的青娥丸含藥血清對(duì)人成骨細(xì)胞增殖、分化及礦化的影響[J].中國實(shí)驗(yàn)方劑學(xué)雜志,2015,21(6):165-168.
[12] 范曉茜,陳鋒,楊文娜.基于系統(tǒng)藥理學(xué)和分子對(duì)接探討青娥丸治療絕經(jīng)后骨質(zhì)疏松癥的作用機(jī)制[J].中國骨質(zhì)疏松雜志,2021,27(5):735-741.
[13] 邸學(xué)士,陳昭,賈育松,等.基于網(wǎng)絡(luò)藥理學(xué)探討青娥丸治療絕經(jīng)后骨質(zhì)疏松癥的作用機(jī)制[J].中國骨質(zhì)疏松雜志,2021,27(3):364-371.
[14] 陳賽楠,周芬,黃云梅,等.基于PERK/eIF2α/ATF4/CHOP通路探討健骨顆粒對(duì)UMR-106細(xì)胞內(nèi)質(zhì)網(wǎng)應(yīng)激凋亡的影響[J].康復(fù)學(xué)報(bào),2024,34(1):34-43.
[15] 夏雪,馬陳,沈霖,等.古方青娥丸治療絕經(jīng)后骨質(zhì)疏松癥的臨床療效觀察[J].中國中醫(yī)骨傷科雜志,2016,24(7):20-22.
[16] 王欣燕,劉建紅,黃顯元.青娥丸對(duì)絕經(jīng)后骨質(zhì)疏松癥患者骨密度、骨代謝指標(biāo)和骨硬化蛋白的影響[J].中國骨質(zhì)疏松雜志,2020,26(3):412-415.
[17] 劉玲,翁澤斌,王恒,等.青娥丸方有效成分藥動(dòng)學(xué)-藥效學(xué)相關(guān)性研究[J].中國中藥雜志,2016,41(23):4436-4441.
[18] 楊榮平,鄧改改,羅友成,等.青娥丸不同萃取部位對(duì)成骨細(xì)胞增殖分化及破骨細(xì)胞活性的影響[J].時(shí)珍國醫(yī)國藥,2011,22(11):2588-2590.
[19] Zhang C,Li H,Li J,et al.Oxidative stress:a common pathological state in a high-risk population for osteoporosis[J].Biomed Pharmacother,2023,163:114834.
[20] 林銳鈿,李子涵,古麗莎.內(nèi)質(zhì)網(wǎng)應(yīng)激在骨代謝及其穩(wěn)態(tài)中的作用[J].中華口腔醫(yī)學(xué)研究雜志(電子版),2021,15(5):309-313.
[21] Wei J,Sheng X,Feng D,et al.PERK is essential for neonatal skeletal development to regulate osteoblast proliferation and differentiation[J].J Cell Physiol,2008,217(3):693-707.
[22] Saito A,Ochiai K,Kondo S,et al.Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2[J].J Biol Chem,2011,286(6):4809-4818.

相似文獻(xiàn)/References:

[1]林建立,林移婷,陳耀琦,等.絕經(jīng)后骨質(zhì)疏松患者骨代謝與脂代謝的關(guān)系及血清蛋白組學(xué)研究[J].福建醫(yī)藥雜志,2025,47(02):1.[doi:10.20148/j.fmj.2025.02.001]
　LIN Jianli,LIN Yiting,CHEN Yaoqi,et al.Serum proteomics study on the relationship between bone metabolism and lipid metabolism in postmenopausal osteoporosis[J].FUJIAN MEDICAL JOURNAL,2025,47(03):1.[doi:10.20148/j.fmj.2025.02.001]

備注/Memo

備注/Memo:
基金項(xiàng)目:福州市衛(wèi)健系統(tǒng)科技計(jì)劃項(xiàng)目(2021-S-wq20); 福建省科學(xué)自然基金項(xiàng)目(2022J011318); 福建省衛(wèi)生健康中青年骨干人才培養(yǎng)項(xiàng)目(2020GGB046); 福建省科技創(chuàng)新平臺(tái)項(xiàng)目(福建省創(chuàng)傷骨科急救與康復(fù)臨床醫(yī)學(xué)研究中心,2020Y2014)
通信作者:鄭世雄,Email:[email protected]
更新日期/Last Update: 2025-03-20